Hanyu Pharmaceutical Signs Peptide API Sales Agreement Worth at Least 327 Million Yuan on May 18

GateNews
According to Jin10, Hanyu Pharmaceutical signed a peptide active pharmaceutical ingredient (API) sales framework agreement with a partner on May 18, 2026, with planned sales of at least 327 million yuan. The sales amount represents 33.84% of the company's most recent audited operating revenue.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments